Incyte Corp. 的股份在问题2中下降了51.4%,但到2025年6月,收入增长了16.5%,分析师对公司的未来有分歧。 Incyte Corp.'s stake dropped 51.4% in Q2, but revenue rose 16.5% by June 2025, with analysts split on its future.

Incyte Corporation(INCY)的股份因Sovran顾问有限责任公司(LLC)在Q2减少了51.4%,留下11 504股,价值778 000美元,而捷克国家银行的股份增加了6.4%。 Incyte Corporation (INCY) saw its stake reduced by Sovran Advisors LLC by 51.4% in Q2, leaving it with 11,504 shares valued at $778,000, while the Czech National Bank increased its holding by 6.4%. 出售肿瘤和炎症药物的生物制药公司报告说,截至2025年6月,收入增长了16.46%,保持了强劲的财政健康,净利润率为33.32%,债务与股本比率较低。 The biopharmaceutical company, which markets drugs for oncology and inflammation, reported 16.46% revenue growth as of June 2025 and maintains strong financial health with a 33.32% net margin and low debt-to-equity ratio. 分析师提供混合评分-七“Buy”、十“Hold”、一“Sell”——协商一致的“Hold”和82.53美元的目标价格。 Analysts offer mixed ratings—seven "Buy," ten "Hold," one "Sell"—with a consensus "Hold" and a target price of $82.53. 股票交易额为86.53美元,市场上限为169亿美元,P/E为19.67美元,贝塔为0.75美元,反映出相对稳定。 The stock trades at $86.53 with a market cap of $16.90 billion, a P/E of 19.67, and a beta of 0.75, reflecting relative stability.